Review
Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Affiliations
- PMID: 3079492
Item in Clipboard
Review
Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Oncology (Williston Park).
1987 Nov.
Abstract
Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.
Similar articles
-
'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.Bone Marrow Transplant. 2002 Dec;30(12):885-91. doi: 10.1038/sj.bmt.1703772. Bone Marrow Transplant. 2002. PMID: 12476281
-
The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.Bone Marrow Transplant. 1997 Feb;19(3):221-6. doi: 10.1038/sj.bmt.1700646. Bone Marrow Transplant. 1997. PMID: 9028549
-
[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].Ai Zheng. 2006 Apr;25(4):486-9. Ai Zheng. 2006. PMID: 16613686 Chinese.
-
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.Semin Oncol. 2000 Feb;27(1 Suppl 1):14-22. Semin Oncol. 2000. PMID: 10697039 Review.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.